Engineering Smarter Antibodies: A Global Team Anchoring the Future of Immunotherapy in Montreal

Discover Ability Biotherapeutics in the latest issue of Insights magazine!

We’re excited to share a feature on Ability, our next-generation antibody company—and the international team that chose Montréal to design the immunotherapies of tomorrow. Our proprietary AbiLeap™ platform combines AI with intelligent antibody design to create logic-gated therapeutics: molecules that are precise, effective, and safer for patients living with cancer or autoimmune diseases.

At Ability, biotech entrepreneurs, antibody engineers, AI specialists, and immunologists come together around a bold vision: AI alone can’t design better drugs—but guided by expert drug developers, it can reshape immunotherapy. Read the full article to learn more about:

• Our scientific approach and technology
• Our experienced leadership team
• Our commitment to building a next-generation biotech in the heart of Montréal